Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.
Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4.

Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.
Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.

Breast Neoplasm

Antineoplastic Agents

Antiemetics

Quality of Life

Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.

Palonosetron

Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.

Ondansetron

Instituto Nacional de Cancerología

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

Personal diary of symptoms given to the patient

Claudia Arce-Salinas

Attendin physician

Instituto Nacional de Cancerologia de Mexico

Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)

Hodgkin Lymphoma

All patients will be treated with 6 cycles of BV-EPEM

BrentuximabVedotin (BV)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol

Institut Català d'Oncologia, Hospital Duran i Reynals

Hospital Costa del Sol

Hospital Clinic i Provincial de Barcelona

Hospital Vall d'Hebron

Hospital de Basurto

Hospital General Universitario Gregorio Marañon

Hospital Universitario 12 de Octubre

Hospital Universitario La Paz

Hospital Son Llatzer

Hospital Universitario de Salamanca

Hospital Universitario Donostia - Arantzazu

Hospital Universitario Marqués de Valdecilla

Hospital Universitario Virgen del Rocío

Hospital Universitario Miguel Servet

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)

To identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM

To assess the percentage of patients with complete response rate after BV-EPEM treatment.

To evaluate the toxicity of the treatment by measure of number of treatment-related adverse events according to CTCAE v4.0

Evaluation of patient without progression of disease

length of time between date of evidence response and progression of disease or death

To evaluate overall response rate (ORR) based on best response (CR and PR) and the tumor local control rate (CR, PR, and stable disease [SD]) with this treatment regimen.

To assess the type, frequency, severity and relationship of adverse events (AEs) to this treatment regimen.

evaluation of patients alive after first dose of treatment and follow up

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Takeda

For the "10,000 steps" group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.
For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement.

This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.

Breast Cancer Female

Adriamycin Toxicity

Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call

10,000 steps

Participants will receive the ACC/AHA exercise guidelines

Usual Care

Johns Hopkins Hospital

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer Who Will be Treated With Anthracyclines

Development of left ventricular dysfunction, assessed by echocardiogram and defined as a decrease in global longitudinal strain between the baseline echocardiogram and the echocardiogram obtained post-treatment with an anthracycline.

Cardiorespiratory fitness/peak oxygen consumption measured using a metabolic stress test

Dual-energy x-ray absorptiometry scan will be performed using standard procedures

Functional Assessment of Cancer Therapy-Breast survey will be administered upon completion of therapy to assess for change in quality of life. Each question on the questionnaire ranges from 0 to 4. The least score is 0 and the maximum is 148 points. Higher scores indicate a higher quality of life.

Change in physical activity with the intervention will be assessed by the Rapid Assessment of Physical Activity questionnaire. This is scored from 1 to 7 with 7 being the most active.

Multidimensional Fatigue Symptom Inventory-Short Form will be used to assess for change in fatigue. Scores for each question range from 0 to 4. The maximum total fatigue score is 72. The higher the score, the more fatigued one is.

Analysis will be performed to assess the impact that receiving motivational text messages has on increasing the amount of physical activity performed/number of daily steps achieved.

Analysis will be performed to assess the impact of weekly telephone calls on increasing the amount of physical activity/number of daily steps achieved

Analysis will be performed to assess the impact that engaging in 30 minutes of daily exercise has on increasing the amount of physical activity performed/number of daily steps achieved

Difference in troponin levels in the the two groups post treatment

adriamycin/fatigue

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

Ginger Control of Chemotherapy Induced Nausea and Vomiting

Database tanaman obat terlengkap yang didukung oleh sains